We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Clontech Licenses CRISPR/CAS9 Technology From Broad Institute

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Clontech Licenses CRISPR/CAS9 Technology From Broad Institute"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

"Clontech is pleased to be able to provide innovative tools for CRISPR/Cas9 gene editing under our Guide-it™ brand," commented Carol Lou, General Manager of Clontech Laboratories, Inc. "We believe that CRISPR/Cas9 technology represents a significant improvement over existing genome editing tools, reaching a new level of targeting, efficiency, and in particular ease of use. It is destined to become as valuable and widely utilized as RNAi; perhaps more so."

Clontech's initial product offering includes Guide-it kits for in vitro production and screening of single guide RNAs (sgRNAs) and a method to confirm the presence of targeted mutations using direct PCR and Clontech's Guide-it Resolvase enzyme.